These findings also indicate that PCSK9 is a host factor for DENV in target cells resident in hypoxic microenvironments and that inhibiting PCSK9 (25) rather than just HMGCoA reductase could be a useful approach to fill the therapeutic void for dengue treatment. This evidence concerns the gene PCSK9 and dengue disease.